# MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

> **NCT06050707** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 80 (estimated)

## Conditions studied

- Anal Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Radiotherapy - Low risk group
- **RADIATION:** Radiotherapy - Standard risk group
- **RADIATION:** Radiotherapy - Intermediate risk group
- **RADIATION:** Radiotherapy - High risk group

## Key facts

- **NCT ID:** NCT06050707
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-29
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050707, "MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06050707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*